-

01:05:26 PM

LIVE Real Time AGNPF Stock Market News

AGNPF - AGNPF

04/08/21 7:00 AM

OTC : AGNPF

Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") a clinical stage pharmaceutical development company, is pleased to announce that it plans to formalize discussions with the U.S.

RHEA-AI

neutral

04/06/21 8:00 AM

OTC : AGNPF

Algernon Pharmaceuticals Announces Appointment of Global Expert Dr. Steven L. Wolf for DMT Stroke Program

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") a clinical stage pharmaceutical development company, is pleased to announce that it has appointed Dr. Steven L. Wolf, a global

RHEA-AI

neutral

03/31/21 8:00 AM

OTC : AGNPF

Algernon Pharmaceuticals Announces Topline Data From its Phase 2b/3 COVID-19 Trial of Ifenprodil

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") a clinical stage pharmaceutical development company, is pleased to announce topline data from the Phase 2b part of its Phase 2b/3

RHEA-AI

neutral

03/29/21 7:02 AM

OTC : AGNPF

Algernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") a clinical stage pharmaceutical development company is pleased to announce that it has been added to the Horizons Psychedelic

RHEA-AI

neutral

03/17/21 7:00 AM

OTC : AGNPF

Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon"), a clinical stage pharmaceutical development company, is pleased to announce that it has filed a pre-IND (Investigational New

RHEA-AI

neutral

03/11/21 7:41 AM

OTC : AGNPF

Algernon Pharmaceuticals Provides Update on Timing of Topline Results for Phase 2b/3 COVID-19 Trial of Ifenprodil

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon"), a clinical stage pharmaceutical development company, announces that it expects to report its topline results for the Phase 2b

RHEA-AI

neutral

03/05/21 7:31 PM

OTC : AGNPF

Algernon Pharmaceuticals Announces Increase and Close of Private Placement

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") a clinical stage pharmaceutical development company is pleased to announce that it has increased and completed its previously

RHEA-AI

neutral

03/03/21 8:00 AM

OTC : AGNPF

Algernon Pharmaceuticals CEO and Dr. David Nutt to Discuss DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon"), a clinical stage pharmaceutical development company, is pleased to announce that Algernon's CEO Christopher J. Moreau and DMT

RHEA-AI

neutral

03/02/21 10:18 PM

OTC : AGNPF

Algernon Pharmaceuticals Announces Private Placement

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") a clinical stage pharmaceutical development company is pleased to announce a non-brokered private placement of 10,800,000 units

RHEA-AI

neutral

03/01/21 8:00 AM

OTC : AGNPF

Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK)

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") a clinical stage pharmaceutical development company announces that it has awarded the contract for its Phase 1 stroke program

RHEA-AI

neutral